Early Phthalates Exposure in Pregnant Women Is Associated with Alteration of Thyroid Hormones

Po-Chin Huang1,2*, Chih-Hsin Tsai1, Wei-Yen Liang1, Sih-Syuan Li1, Han-Bin Huang3, Pao-Lin Kuo4
1 National Environmental Health Research Center, National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli, Taiwan, 2 Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 3 School of Public Health, National Defense Medical Center, Taipei, Taiwan, 4 Department of Obstetric and Gynecology, National Cheng Kung University Hospital and College of Medicine, Tainan, Taiwan

These authors contributed equally to this work.
*pchuang@nhri.org.tw

Abstract

Introduction
Previous studies revealed that phthalate exposure could alter thyroid hormones during the last trimester of pregnancy. However, thyroid hormones are crucial for fetal development during the first trimester. We aimed to clarify the effect of phthalate exposure on thyroid hormones during early pregnancy.

Method
We recruited 97 pregnant women who were offered an amniocentesis during the early trimester from an obstetrics clinic in southern Taiwan from 2013 to 2014. After signing an informed consent form, we collected amniotic fluid and urine samples from pregnant women to analyze 11 metabolites, including mono-ethyl phthalate (MEP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-(2-ethylhexyl) phthalate (MEHP), mono-butyl phthalate (MnBP), of 9 phthalates using liquid chromatography/tandem mass spectrometry. We collected blood samples from each subject to analyze serum thyroid hormones including thyroxine (T4), free T4, and thyroid-binding globulin (TBG).

Results
Three phthalate metabolites were discovered to be >80% in the urine samples of the pregnant women: MEP (88%), MnBP (81%) and MECPP (86%). Median MnBP and MECPP levels in pregnant Taiwanese women were 21.5 and 17.6 μg/g-creatinine, respectively, that decreased after the 2011 Taiwan DEHP scandal. Results of principal component analysis suggested two major sources (DEHP and other phthalates) of phthalates exposure in pregnant women. After adjusting for age, gestational age, TBG, urinary creatinine, and other phthalate metabolites, we found a significantly negative association between urinary MnBP...
levels and serum T₄ (β = –5.41; p-value = 0.012; n = 97) in pregnant women using Bonferroni correction.

**Conclusion**

We observed a potential change in the thyroid hormones of pregnant women during early pregnancy after DnBP exposure. Additional study is necessitated to clarify these associations.

**Introduction**

Phthalates are used in many daily products including plastics, toys, medical equipment, personal care products, cosmetics, and food package film [1]. Reports on the endocrine-related effects of phthalate exposure on human health, especially for susceptible populations, have rapidly increased that are worthy of further investigation [2]. In 2011, a scandal involving phthalate-tainted food occurred in Taiwan; it was controlled within 3 months through actions including the restriction and regulation of six commercial phthalates [3]. Several studies have revealed that the 2011 Taiwan di-(2-ethylhexyl) phthalate (DEHP) scandal has permanently changed the profiles of phthalate exposure and potential health effects in DEHP-exposed newborns and children, as well as in the general Taiwanese population [1, 4–6], but little information is available for pregnant women.

Epidemiologic studies have revealed that phthalates may negatively alter thyroid hormones in general and susceptible populations, especially in pregnant women [4, 7–9]. Some experimental studies have further confirmed that certain phthalates, including DEHP and di-2-ethylhexyl phthalate (DnBP), have antithyroid activity occurring through several possible mechanisms, such as interruption of the sodium-iodide symporter and upregulation of thyroid-related genes [10–11]. Maternal thyroid hormones in early pregnancy played a critical role in early fetal development [12–14]. Some studies have further indicated that pregnant women might be exposed to different phthalate levels during different stages of pregnancy, and that this might affect fetal development during critical windows [9,15–16]. We aimed to evaluate the effects of phthalates exposure on thyroid hormones in early pregnancy and analyze phthalate exposure levels in pregnant women after the 2011 Taiwan DEHP scandal by testing urine and amniotic fluid samples.

**Materials and Methods**

**Ethics Statement**

The study protocol was approved by the research ethics committee of the National Health Research Institutes (No. EC1020302) and Institutional Review Board of National Cheng Kung University Hospital (No. A-ER-102-104) in Taiwan, and a written informed consent was obtained from each participant prior to study enrollment.

**Subject Recruitment**

Our participants were pregnant women for whom the blood biochemical examination (alpha fetal protein and free β-hCG) results were abnormal, or whose advanced maternal age (> 35 years) suggested the need to undergo amniocentesis based on the clinical suggestion of gynecologists at the National Cheng Kung University Hospital. Pregnant women with preeclampsia and abnormal chromosome diseases (e.g., Down’s syndrome) were excluded. All the fetuses of
our participants were diagnosed as healthy after examination of chromosomes in their amniotic fluid samples. All participants (N = 97) were interviewed and received explanations of the benefits and risks of participating in the Tainan Birth Cohort (TBC 2013–14) project. All the fetuses of our participants were diagnosed as healthy after we examined the chromosomes in their amniotic fluid samples.

**Questionnaire**

During an interview, participants provided information regarding personal characteristics (age, education, occupational history, social economic status, etc.), pregnancy history (gestational age, time to pregnancy, menarche age, and parity), lifestyle habits (tobacco use, passive smoking, and alcohol intake), and exposure history (whether exposed to DEHP-tainted products before the DEHP episode and nutritional supplement consumption, such as a vitamin complex and folic acid) to adjust for potential confounding factors.

**Sample Collection**

At the beginning of amniocentesis, gynecologists drew 2 mL of amniotic fluid into a 5-mL polypropylene (PP) syringe, and immediately transferred it into amber glass bottles to analyze the levels of phthalate metabolites. Approximately 30 min before or after performing amniocentesis, we collected 20–30 mL urine samples in disposal PP vessels and immediately transferred them into 12 mL amber glass bottles for analysis of phthalate metabolites and creatinine. To prevent contamination of the urine samples, all amber glassware was prewashed with methanol, acetonitrile, and acetone. Furthermore, we obtained 20-mL blood samples from each participant in the clinic via venipuncture that were placed into PP tubes containing no anticoagulant and allowed to settle for 40 minutes, and additional centrifugation was then performed. Serum samples were analyzed for thyroid hormone and its binding globulin. All serum and urine samples were collected from each subject at the same time and stored at −80°C and −20°C, respectively.

**Analysis of Phthalate Metabolites**

We used a published method [1] to analyze the levels of 11 urinary phthalate metabolites using an isotope dilution standard and online solid phase extraction, coupled with liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Eleven phthalate metabolites including mono-benzyl phthalate (MBzP), mono-iso-butyl phthalate (MiBP), mono-n-butyl phthalate (MnBP), mono-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-(2-carboxymethylhexyl) phthalate (MCMHP), mono-ethyl phthalate (MEP), mono-methyl phthalate (MMP), and mono-iso-nonyl phthalate (MiNP) representing exposure to 7 commonly used phthalates (DEHP, DnBP, DiBP, BBzP, DEP, DMP, and DiNP) were measured in each urine sample. After the urine sample was thawed and sonicated for 10–15 min, the urine sample (100 μL) was loaded into a 2-mL glass vial containing ammonium acetate (AA; 20 μL, >98%; Sigma Aldrich Lab, Inc, St. Louis, MO, USA), β-glucuronidase (10 μL, Escherichia coli K12, Roche Biomedical, Mannheim, Germany), 11 mixed phthalate metabolite standards, and 10 mixed isotopic (13C4) phthalate metabolite standards as the internal standards (100 μL; Cambridge Isotope Lab, Inc, Andover, MA, USA). After the sample was incubated (37°C, 90 min), a 270-μL solution (5% acetonitrile [ACN], Merck, Darmstadt, Germany) with 0.1% formic acid (FA, Merck, Darmstadt, Germany) was added and sealed with a PTFE cap for analysis. We used an online system that was coupled with LC-ESI-MS/MS (Agilent 1200/API 4000, Applied Biosystems, Foster
City, CA, USA). We used two columns in our online system. One C18 column (Inertsil ODS-3, 33 × 4.6 mm, 5 μm, GL Science, Tokyo, Japan) was used to extract and clean our sample, and an analytical column (Inertsil Ph, 150 × 4.6 mm, 5 μm, GL Science, Tokyo, Japan) was used to separate different phthalate metabolites. The gradient program of the clean-up column was listed as follows: 100% solution A (5% ACN + 0.1% FA) (0–7 min), 100% solution B (90% ACN + 0.1% FA) (7–9 min), 100% solution A (9–10 min) and continued to 12 min. The flow rate was set at 1000 μl/min. The analytical column gradient program was listed as follows: 100% solution C (50% ACN + 10 mmole AA) (0–3.6 min), 100% solution D (95% ACN + 10 mmole AA) (3.6–8.6 min), 100% solution C (8.6–9 min) and continued to 12 min. We used a negative multiple reaction–monitoring model for mass spectroscopy detection. The ion pair of each phthalate metabolites was listed as follows: MEHP (277/134), MEOHP (291/143), MEHHP (293/121), MECPP (307/159), MCMHP (307/113), MnBP (221/71), MiBP (221/71), MEP (193/121), MiNP (291/121), MBzP (255/183), and MMP (179/107). The detection limits of the metabolites were 0.7, 0.3, 0.3, 0.3, 0.1, 1, 1, 0.3, 0.1, 0.3, and 0.3 ng/mL, respectively. One blank, repeated quality control (QC) sample was included in each batch of analyzed samples. Concentrations of blank samples was to be less than 2 fold the method detection limit. The QC sample was spiked in pooled urine samples with a mixture of phthalate metabolite standards (20–50 ng/mL) in each sample. The relative percent difference for the repeated sample, as well as recovery of the QC sample, was to be less than ±30%.

Serum Thyroid Hormones and Creatinine Analysis
Urinary creatinine levels and serum thyroid hormones were measured by a Taiwan Accreditation Foundation–certified laboratory (No.: 1447 & 1673), which had been recognized by the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement [17]. Two milliliters of urine that had been stored at −20°C was analyzed using combined clinical chemistry and immunoassay tests (Modular Analytics Serum Work Area; Roche Diagnostics). One milliliter of serum sample was analyzed for triiodothyronine (T₃), thyroxin (T₄), free T₄ (FT₄), thyroid stimulating hormone (TSH), and thyroid binding-globulin (TBG) using an electrochemiluminescence immunoassay (ECLIA) (Elecsys 2010 and Modular Analytics E170; Roche Diagnostics). We analyzed the urinary creatinine again to confirm if an abnormal creatinine level was reported.

Statistical Analysis
Demographic factors, exposure, and outcome variables were evaluated for normal distribution and outliers. Age, age of menarche, length of gestation, time to pregnancy, and pregnancy and delivery history were evaluated as continuous variables, while education, annual family income, smoking status, pre- and post-pregnancy alcohol consumption, residential and workplace building characteristics, vitamin and folic acid consumption, and DEHP-tainted product consumption history were evaluated as nominal variables. We calculated not detectable (ND) levels as half of the detection limit of each phthalate metabolite, and detectable rate as the number of urine samples with levels of each phthalate metabolite higher than the detection limit divided by all analyzed urine samples. We calculated sum (∑) DEHP metabolites by the amounts of all five DEHP metabolites, and ∑DBP metabolites by adding concentrations of MnBP and MiBP. All measured phthalate metabolites were logarithm (log)-transformed to approximate a normal distribution. The T₄ and TBG concentrations were a normal distribution, while TSH, T₃, and free T₄ or urinary creatinine levels were log-transformed to approximate a normal distribution. Pearson correlation coefficients were used to assess the associations among age, gestation, each thyroid hormone level, and each urinary phthalate
metabolite level. Principal component analysis (PCA) was applied to assess the potential sources of exposure to different phthalates. Physiological factors or variables significantly correlated with urinary phthalate metabolites or thyroid hormones were included in the multiple regression model. We included most important sources of phthalates exposure in our final model. We also evaluated the correlation between adjusted creatinine and unadjusted phthalate metabolite levels. In addition, a multiple linear regression analysis was used to adjust for significant covariates. We used both adjusted creatinine and unadjusted phthalate metabolite levels in different regression models to evaluate the influence of urinary creatinine. We used Bonferroni correction to express the two-sided significance level at $P < 0.05/k$ (k: the number of phthalate metabolites in the regression model). Commercially available statistical software (SPSS version 22.0; SAS Institute, Cary, NC, USA) was used for statistical analysis.

Results

Demographic Characteristics of Participants

The participants’ mean age and age of menarche were 35.1 ± 3.5 (25.5–43.4) years and 13.1 ± 1.1 (11–16) years, respectively. Upon recruitment, the average duration of gestation was 18.3 ± 1.4 (16–24) weeks. The average number of pregnancies and childbirths per participant were 1.8 ± 0.9 and 0.7 ± 0.5, respectively. Most of our subjects were well educated (95.9% graduated from university) and were considered to have greater than a middle-class socioeconomic background (83.5%). Before pregnancy, only 2 participants were active smokers (2.1%); 16 participants reported passive smoke exposure (16.5%); and 1% drank alcohol. After pregnancy, none was an active smoker or drank alcohol, but 21 participants reported passive smoke exposure (21.6%). Approximately 16.5% had stayed in a newly decorated home 1 year before the study; 13.4% had eaten DEHP-tainted products, mainly fruit jam before the 2011 Taiwan DEHP scandal. A total of 37.1% had taken a vitamin complex or folic acid during pregnancy. None had a family or medical history of thyroid diseases (Table 1). We found no significant difference in the levels of the 11 urinary phthalate metabolites between different confounders, e.g., passive smoking, nutrition supplementation, or home or workplace characteristics. None of our participants was working at a plastics-, chemical-, or cosmetics-related job.

Levels of 11 Phthalate Metabolites in Urine and Amniotic Fluid Samples

The detectable rates of 11 phthalate metabolites in all urine samples ranged from 15.3% to 87.8% and were as follows: MEP (87.8%), MnBP (80.6%), MiBP (65.3%), MEHP (71.4%), MEHHP (75.5%), MEOHP (76.5%), MECPP (85.7%), MCMHP (24.5%), MMP (69.4%), MBzP (18.4%), and MiNP (15.3%) (Table 2). Distribution and median levels with and without creatinine adjustments for the 11 urinary phthalate metabolites in all participants were as follows: MnBP, 21.5 µg/g creatinine (12.3 ng/mL); MiBP, 7.4 µg/g creatinine (4.4 ng/mL); MEP, 21.0 µg/g creatinine (11.2 ng/mL); MEHP, 7.2 µg/g creatinine (5.1 ng/mL); MEHHP, 11.1 µg/g creatinine (5.7 ng/mL); MEOHP, 9.4 µg/g creatinine (5.6 ng/mL); MECPP, 17.6 µg/g creatinine (9.5 ng/mL); and MMP, 6.2 µg/g creatinine (3.4 ng/mL). However, MBzP, MCMHP, or MiNP was not detectable (ND) (Table 2). Levels of urinary MnBP and MEP were the highest of all measured metabolites, followed by MECPP, MEHHP, and MEOHP, indicating that the participants were predominantly exposed to the phthalates DnBP, DEP and DEHP. We found that levels of phthalate metabolites in our subjects increased after adjusting the creatinine levels. In addition, the median creatinine level for our participants was 50 mg/dL; however, approximately 30% of the participants had creatinine levels lower than 30 mg/dL. Because positive and high correlations were found between adjusted and unadjusted creatinine levels for all urinary phthalate metabolites (S1 Table), we used the unadjusted creatinine phthalate metabolites
Table 1. Demographic Characteristics of Participating Pregnant Taiwanese Women (N = 97).

| Characteristics                                      | Mean ± SD/N (%) |
|------------------------------------------------------|-----------------|
| **Continuous variables (Mean ± SD)**                 |                 |
| Age (y)                                               | 35.1 ± 3.5      |
| Menarche age (y)                                     | 13.1 ± 1.1      |
| Duration of gestation (weeks)                        | 18.3 ± 1.4      |
| Time to pregnancy (months)                           | 27.8 ± 30.1     |
| **Pregnancies and births**                           |                 |
| Number of current pregnancies                        | 1.8 ± 0.9       |
| Number of current births                             | 0.7 ± 0.5       |
| **Nominal variables [N (%)]**                         |                 |
| Education                                            |                 |
| < Junior high school                                 | 1 (1.0)         |
| Senior high school                                   | 3 (3.1)         |
| ≥ University/ College                                | 93 (95.9)       |
| Annual family income [USD]$^a$                       |                 |
| < 15,600                                             | 16 (16.5)       |
| 15,600–31,250                                        | 51 (52.6)       |
| ≥ 31,250                                             | 30 (30.9)       |
| Active smoker$^b$                                    |                 |
| Before pregnancy                                     | 2 (2.1)         |
| After pregnancy                                      | 0               |
| Passive smoker                                       |                 |
| Before pregnancy                                     | 16 (16.5)       |
| After pregnancy                                      | 21 (21.6)       |
| Drank alcohol$^c$                                    |                 |
| Before pregnancy                                     | 1 (1.0)         |
| After pregnancy                                      | 0               |
| New decoration of residence or workplace during past 1 y$^d$ |             |
| Home                                                 |                 |
| Moving to a new house                                | 16 (16.5)       |
| Recently decorated                                   | 19 (19.6)       |
| Workplace                                            |                 |
| Moving to a new workplace                            | 2 (2.1)         |
| Recently decorated                                   | 9 (9.3)         |
| Have ever consumed DEHP-tainted products$^e$         |                 |
| Yes                                                  | 13 (13.4)       |
| No                                                   | 84 (86.6)       |
| Have ever taken a vitamin complex$^f$                 |                 |
| Yes                                                  | 39 (40.2)       |
| No                                                   | 58 (59.8)       |
| Have ever taken folic acid$^f$                        |                 |
| Yes                                                  | 36 (37.1)       |
| No                                                   | 61 (62.9)       |
| Family or personal medical history of thyroid disease|                 |
| Yes                                                  | 0 (0)           |

(Continued)
levels for further analysis to avoid potential bias from urinary creatinine. We found that median levels of urinary MBP (MiBP + MnBP), MEHP, MEP, and MMP in our participants (TBC 2013–14) decreased 4.8-, 5-, 1.9-, and 2-fold, respectively, compared with those in TBC 2005–06 [8], but similar levels were observed for urinary MBzP (Fig 1 and S2 Table).

Few phthalate metabolites were detected in amniotic fluid sample (Table 2). The detectable rates of 11 phthalate metabolites in all amniotic fluid samples ranged from 0% to 37.1% (MnBP) and 49.5% (MEHP). We found that only the MEHP and MnBP metabolites were at the 75th percentile (9.62 and 2.53 ng/mL, respectively) and were above the LOD.

**Thyroid Hormone Level**

Approximately 90% of the participants’ thyroid hormone levels for T₃, T₄, and TSH were within reference values for the general population (Table 3). We found the FT₄ levels during the first quartile (0.69 ng/dL) for our participants were below the lowest level for the general population, indicating that around 27% of our participants might have had a mild thyroxine insufficiency (i.e., subclinical hypothyroidism).

### Table 2. Distribution of creatinine-adjusted levels (μg/g creatinine, or ng/ml) of urinary phthalate metabolites in pregnant women (N = 97), and amniotic fluid phthalate metabolites (ng/ml).

| Phthalate metabolites | Maternal urine | Amniotic fluid |
|-----------------------|----------------|----------------|
| Detectable rate (%)   | 25th | 50th | 75th | 95th | Max | 75th | 95th | Max |
| MMP                   | 69.1 | ND  | 63.3 (3.4) | 14.4 (6.8) | 49.3 (51.6) | 115 (75.3) | 1.0 | ND | ND | 5.29 |
| MEP                   | 87.6 | 7.6 | 21.0 (11.5) | 43.2 (22.7) | 233 (246) | 693 (686) | 3.1 | ND | ND | 3.21 |
| MiBP                  | 64.9 | ND  | 7.4 (4.3) | 19.4 (12.2) | 69.9 (50.8) | 274 (142) | 0 | ND | ND | ND |
| MnBP                  | 80.4 | 9.6 (3.2) | 21.0 (12.1) | 42.8 (25.6) | 73.5 (82.3) | 180 (102) | 37.1 | 2.53 | 7.17 | 12.52 |
| MBzP                  | 18.6 | ND  | ND | ND | 12.8 (6.8) | 95.8 (51.7) | 0 | ND | ND | ND |
| MEHP                  | 71.1 | ND  | 7.2 (5.0) | 19.8 (9.9) | 42.3 (19.6) | 76.6 (46.0) | 49.5 | 9.62 | 24.4 | 29.78 |
| MEHP                  | 75.3 | 2.2 (1.1) | 10.8 (5.7) | 17.7 (12.0) | 33.2 (30.2) | 81.3 (68.9) | 0 | ND | ND | ND |
| MEOHP                 | 75.3 | 3.2 (1.2) | 9.5 (5.6) | 16.4 (11.4) | 35.7 (27.5) | 56.2 (36.4) | 0 | ND | ND | ND |
| MECPP                 | 85.6 | 8.7 (4.0) | 17.7 (9.7) | 30.7 (20.4) | 101 (33.9) | 840 (143) | 1.0 | ND | ND | 2.07 |
| MCMHP                 | 24.7 | ND  | ND | ND | 1.7 (1.2) | 6.4 (5.3) | 601 (102) | 0 | ND | ND | ND |
| MiNP                  | 15.5 | ND  | ND | ND | 27.7 (10.3) | 56.5 (13.1) | 5.2 | ND | 2.49 | 8.15 |

**Abbreviations:** mono-methyl phthalate (MMP), mono-ethyl phthalate (MEP), mono-isobutyl phthalate (MiBP), mono-n-butyl phthalate (MnBP), mono-benzyl phthalate (MBzP), mono-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxo-hexyl) phthalate (MEOHP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-(2-carboxymethylhexyl) phthalate (MCMHP), mono-iso-nonyl phthalate (MiNP).

**Creatinine unadjusted phthalate metabolites value is presented in parentheses. Not detectable (ND) was calculated as half of detection limit (LOD).**
Correlation between Phthalate Metabolites and Thyroid Hormones

We found a significantly positive correlation between T₃ and T₄ levels (R = 0.423; p-value < 0.05), T₃ and FT₄ levels (R = 0.249; p-value < 0.05), T₃ and TBG levels (R = 0.582; p-value < 0.001), and T₄ and TBG levels (R = 0.642; p-value < 0.001) (Table 4). A marginally significant and negative correlation was found between T₄ and urinary MnBP (R = −0.179; p-value < 0.10). Increasing age was correlated with T₃ levels (R = 0.212; p-value < 0.05). Urinary MiBP was significantly and positively associated with FT₄ (R = 0.313; p-value < 0.05) and age (R = 0.216; p-value < 0.05). In addition, no correlation was found between gestational age and thyroid hormone levels or urinary phthalate metabolites. Therefore, these parameters were considered continuous variables for further adjustment.

Table 3. Distribution of serum thyroid hormones and urinary creatinine in participants (N = 97) at the first trimester.

| Items          | Selected percentiles | Reference range a |
|----------------|----------------------|-------------------|
|                | Min | 5th | 25th | 50th | 75th | 95th | Max   |            |
| TSH (μIU/ml)   | 0.01| 0.11| 0.73 | 1.25 | 1.70 | 2.79 | 6.15  | 0.35–4.94 |
| T₃ (ng/dl)     | 43  | 76  | 106  | 126  | 144  | 184  | 259   | 58–159    |
| T₄ (μg/dl)     | 4.60| 6.90| 8.10 | 8.79 | 10.16| 11.54| 13.16 | 4.87–11.72|
| Free T₄ (ng/dl)| 0.52| 0.57| 0.69 | 0.77 | 1.01 | 1.11 | 1.17  | 0.7–1.48  |
| TBG (μg/ml)    | 16.1| 20.3| 30.0 | 36.2 | 41.4 | 50.8 | 60.8  | 15.8–25.4 |
| Creatinine (mg/dl) | 8   | 13  | 25  | 50  | 96  | 168 | 229   | 60–250 |

Abbreviations: TSH: thyroid stimulating hormone; T₃: triiodothyronine; T₄:Thyroxine; Free T₄: free thyroxine; TBG: thyroxine-binding globulin.

aClinical normal range for normal adults.

doi:10.1371/journal.pone.0159398.t003
Table 4. Pearson correlation between thyroid hormone, age, duration of gestation, time to pregnancy and urinary phthalate metabolite levels (ng/mL, N = 97).  

| Parameters | Urinary phthalate metabolites | Thyroid hormone | Pregnant women |
|------------|-------------------------------|----------------|----------------|
|            | MMP  | MEP  | MiBP | MnBP | MEHP | MEHHP | MEOHP | MECPP | MBzP | MCMHP | MiNP | TSH | T3 | T4 | Free T4 | TBG | Age | Gestation | Time to pregnancy |
| MMP        |      | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MEP        | 0.313* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MiBP       | 0.579* 0.354* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MnBP       | 0.344* 0.284* 0.535* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MEHP       | 0.530* 0.211* 0.583* 0.380* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MEHHP      | 0.448* 0.298* 0.499* 0.474* 0.669* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MEOHP      | 0.388* 0.400* 0.427* 0.448* 0.563* 0.673* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MECPP      | 0.195 0.192 0.195 0.196 0.524* 0.551* 0.522* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MBzP       | 0.227 0.319* 0.329* 0.300* 0.320* 0.136 0.385* 0.071 | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MCMHP      | 0.192 0.165 0.227* 0.097 0.315* 0.138 0.273* 0.177 0.298* | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |
| MiNP       | -0.047 0.141 0.150 -0.142 -0.099 -0.271* 0.053 -0.234* 0.145 0.087 | 1    |      |      |      |        |        |        |      |      |      |      |      | | | | | | | | |

Thyroid hormone

| TSH | 0.088 0.043 -0.123 0.142 -0.014 0 -0.098 -0.056 0.001 0.072 -0.032 | 1 |
| T3  | 0.093 0.052 0.107 0.017 0.080 -0.042 0.029 -0.090 -0.032 -0.048 0.180 -0.006 | 1 |
| T4  | -0.069 -0.051 0.021 -0.179* -0.036 -0.076 0 0.020 -0.084 0.226* 0.238* -0.065 0.423* | 1 |
| Free T4 | 0.078 0.121 0.313* -0.100 0.100 -0.149 -0.137 -0.090 -0.034 -0.151 0.410* -0.042 0.249* 0.131 | 1 |
| TBG | -0.087 -0.038 0.024 -0.019 0.042 -0.026 0.001 0.045 -0.092 0.016 0.078 0.070 0.582* 0.642* 0.088 | 1 |

Pregnant women

| Age | 0.204* 0.123 0.216* -0.009 0.093 0.043 0.100 -0.050 -0.016 0.062 0.104 0.041 0.212* 0.078 0.104 0.166 | 1 |
| Gestation | -0.054 -0.110 0.002 -0.046 -0.070 -0.094 0 0.002 -0.087 -0.100 -0.068 -0.048 -0.004 0.143 -0.065 0.003 0.030 | 1 |
| Time to pregnancy | -0.041 0.026 0.130 -0.140 0.073 -0.020 0.025 0.025 -0.122 0.191 0.198 0.061 0.079 0.144 0.158 0.050 0.247* 0.095 | 1 |

*Pearson correlation coefficients: * P < 0.05; # P < 0.10.

bAbbreviations were shown in the footnote of Tables 2 and 3.

doi:10.1371/journal.pone.0159398.t004
Principal Component Analysis (PCA)

Fig 2 illustrates the PCA of 11 phthalate metabolites in this study. Three principal components (PCs) accounted for 35.5% (PC1), 16.6% (PC2), and 12.1% (PC3) of the total variance. We found that PC1 was dominated by three DEHP metabolites (MEHP, MEHHP, and MEOHP); PC2 by the group of MnBP, MiBP, MEP, MMP, and MBzP; and PC3 by the group of MECPP and MCMHP. We also found profiles of major exposure to the sum DEHP metabolites, MEP and the sum of DBP metabolites (MnBP and MiBP) accounted for 32.7%, 31.5%, and 25.5%, respectively, of the total concentration of 11 phthalate metabolites in our participants (S1 Fig).

Regression Analysis

Fig 3 shows a scatter plot of serum T4 levels, as well as log urinary MnBP levels, with adjusted (triangle, dashed line) and unadjusted creatinine levels (circle, solid line) for each participant. To identify the major factors contributing to serum T4 concentrations, we used a multivariate regression model to examine the association between thyroid hormone levels and urinary phthalate metabolites (Table 5). After adjusting for age, gestational age, TBG, urinary creatinine, and three phthalate metabolites (MECPP, MEP, MiBP) in our subjects, urinary MnBP levels showed a significantly negative association with T4 (T4: $\beta = -5.41; SE: 2.1; 95\% CI: -9.59$ to $-1.24; p$-value = 0.012; $n = 97$) in the participating pregnant women (Model 1). Meanwhile, a similar result was observed if using a creatinine-based phthalate metabolite level (Model 2).

Discussion

We observed 5-fold decreases in the levels of urinary MBP and MEHP in pregnant Taiwanese women (2013–14) after the 2011 Taiwan DEHP scandal in comparison with those reported in 2005–06 [8]. We found a significantly negative association between urinary MnBP and serum T4 in the pregnant women during the first trimester after adjusting for age, TBG, gestational
age, and exposure to other phthalates. Our data suggest that DnBP exposure may alter serum 
T4 levels during early pregnancy.

Four studies previously conducted in Taiwan (2005–2006) [8], the United States (2010– 2012) [18], Canada (2008–2011) [19], and Puerto Rico (2010–2012) [20] provided exposure 
profiles for some phthalates in early pregnancy (Fig 1 & S2 Table). Our data showed that uri-
nary MBP (MnBP + MiBP) and MEHP levels in our participants (Taiwan 2013–14) were 
nearly 5-fold lower than those reported in a previous study conducted in Taiwan from 2005 to 
2006 [8], before the 2011 Taiwan DEHP scandal. Although DBP and DEHP exposure levels 
may vary by person, be correlated with lifestyle, or gradually decrease [21], the significant drop 
in metabolites of DEHP and DBP exposure in pregnant Taiwanese women might be related to 
the regulation and restriction of DEHP and DBP usage in certain products after the 2011 Tai-
wan DEHP scandal that may decrease overall phthalate exposure in the general Taiwanese 
population [1].

Additionally, the exposure levels of MnBP and MEHP in our participants were 1.8- and 
2.6-fold, respectively, higher than those reported in pregnant American women during the first 
trimester [18], while those of MEP and MBzP were lower. A similar phenomenon was found 
for MnBP, MEHP, MEP, and MBzP, if comparing our data to a Canadian study, MIREC [19]. 
Exposure levels for most phthalate metabolites in pregnant Puerto Rican women in the PRO-
TECT study [20] were higher than those reported in Taiwan, the US, and Canada, especially 
for urinary MEP, MnBP, and MECPP levels. However, the exposure profiles of six urinary 
phthalate metabolites in our participants were similar to those reported in China [22]. Some 
studies [23–25] have revealed that exposure to urinary MEP, MBP, and MBzP may be related 
to personal care products (e.g., sunscreen and lotion) and cosmetics (e.g., perfumes, nail polish,
and makeup) in pregnant American women and women globally. Because BBzP is most commonly used in building materials [2], a preference for using marble and wood as flooring in Chinese societies may explain why low levels of MBzP were observed in a Chinese population [22]. Thus, the lower levels of MEP and MBzP exposure in pregnant Taiwanese women may reflect a less intense use of personal care products or cosmetics and less frequent usage of PVC in Taiwanese building materials.

We found a strong correlation for four DEHP metabolites, MEHP, MEHHP, MEOHP and MECPP, but a relative weak correlation for MCMHP. One possible explanation is the low detection rate of urinary MCMHP in our participants (approximately 25%), which is 2.56-fold lower than that of the general female Taiwanese (approximately 64%) [1]. However, all other phthalate metabolites appeared at a detection rate in our pregnant participants that was comparable to that of the general female population. Because MCMHP is a secondary metabolite of DEHP, physiological changes in pregnant women during early pregnancy may alter the metabolic ability of oxidizing DEHP. In addition, we found three principal components that explained 64.2% of the total variance. DEHP being the predominant phthalates in food products [1], food may be the major contributor to PC1 in pregnant Taiwanese women. PC2 consists of complex phthalate metabolites, including MnBP, MiBP, MEP, MMP, and MBzP, and consumer products may contain different phthalates [26]. Personal care products, solvents, and medicine coatings DnBP, DiBP, and DEP [1]; polyvinyl chloride flooring contains BBzP [1]; and milk products, snacks, and noodles contain DMP [27]. This indicates that Taiwanese women in the early stages of pregnancy are exposed to a wide range of phthalates from daily consumer products.

Our data are consistent with several studies on phthalate metabolites in human amniotic fluid samples [28–29]. Three possible reasons exist for the decrease in correlations in the

| Table 5. Multiple linear regression between serum T4 and corresponding urinary phthalate metabolites (N = 97; T4: R² = 0.475). |
|------------------|------------------|------------------|-----------|-----------|
| **Multiple regression** | **T4 (nmol/L)** | **Model 1α** | **Beta** | **SE** | **95% CI** | **P-value** |
| Intercept | -25.5 | 63.3 | -151.2 | 100.2 | 0.688 |
| MnBP (ng/mL) | -5.41 | 2.10 | -9.59 | -1.24 | 0.012 |
| MECPP (ng/mL) | -0.16 | 2.23 | -4.60 | 4.28 | 0.944 |
| MEP (ng/mL) | 0.01 | 2.18 | -4.32 | 4.34 | 0.997 |
| MiBP (ng/mL) | 2.73 | 2.10 | -1.44 | 6.90 | 0.197 |
| Age | -0.37 | 0.45 | -1.26 | 0.53 | 0.416 |
| Gestational age | 81.0 | 49.0 | -16.3 | 178.3 | 0.102 |
| TBG | 1.45 | 0.18 | 1.10 | 1.81 | <0.001 |
| Creatinine | 2.27 | 6.24 | -10.1 | 14.7 | 0.717 |

| **Model 2α** | **Beta** | **SE** | **95% CI** | **P-value** |
|------------------|------------------|------------------|-----------|-----------|
| Intercept | -20.1 | 63.7 | -146.7 | 106.4 | 0.753 |
| MnBP (μg/g-creatinine) | -5.44 | 2.07 | -9.56 | -1.33 | 0.010 |
| MECPP (μg/g-creatinine) | -0.14 | 2.22 | -4.55 | 4.27 | 0.949 |
| MEP (μg/g-creatinine) | -0.02 | 2.16 | -4.31 | 4.28 | 0.994 |
| MiBP (μg/g-creatinine) | 2.69 | 2.07 | -1.41 | 6.80 | 0.195 |
| Age | -0.37 | 0.45 | -1.26 | 0.52 | 0.412 |
| Gestational age | 80.6 | 48.6 | -16.0 | 177.2 | 0.101 |
| TBG | 1.45 | 0.18 | 1.10 | 1.80 | <0.001 |

αMnBP, MECPP, MEP, and MiBP levels; urinary creatinine; and gestational age were log10 transformed.
current study. One is that the difference in the ability of fetuses to metabolize phthalates may vary by species. A strong correlation between MEHP and MnBP in maternal urine and amniotic fluid samples were reported in rats [30–31]. However, some studies demonstrated that different species of mammals can have different placental barriers, such as hemoendothelial and endothelial barriers, leading to dissimilar levels of environmental pollutants in amniotic fluid [32–35]. Rodents are the most frequently used models for placenta research because they possess hemochorial placentas, but these are different from the human placenta and therefore the applicability of these studies is often overvalued [35]. Another study used a human placenta perfusion system to measure the distribution of four phthalate monomers (MEHP, MnBP, MEP, and MMP) between the umbilical cord plasma and placental tissue, and suggested that this distribution depended on their physicochemical properties [36]. A second possible explanation is that the fetal liver might not be highly developed in early pregnancy. In most studies, the amniotic fluid samples contained a low levels of the oxidative metabolites of DEHP. The low detectable rate of the secondary metabolites of DEHP and DiNP reflects the possibility that the development of fetal liver detoxification, like glucuronidation, might be incomplete in early pregnancy [28, 30–31, 37]. Third, one study revealed potential contamination of urinary MEHP in the laboratory [31], meaning that correlations may have been overestimated. Nevertheless, all previous studies have indicated that DEHP and DBP can penetrate placenta and cause uterine exposure in early pregnancy.

We also observed the proportion of subclinical hypothyroidism in our subjects was nearly 2-fold less than (27% versus >50%, Table 3) that reported in a previous study [8]. We found a significantly negative association between urinary MnBP and serum T4 in pregnant women during the first trimester after adjusting for age, TBG, gestational age, and other phthalate exposures. Some studies have reported a negative association between DEHP or DnBP and thyroid hormones (such as T4 and T3) in the general Danish and American population, and in American pregnant women [7,9,38]. One longitudinal study indicated that significant inverse associations were observed between FT4 and DEHP metabolites during the third trimester [9]. The influence of a low-dose phthalate exposure on thyroid hormones was consistent with epidemiologic studies that indicated the thyroid gland could be affected by multiple phthalate exposures. About 9.3% of TSH level in our subject was above 2.5 μIU/ml, which is a new guideline of subclinical hypothyroidism in the infertile female [39]. Subclinical hypothyroidism or phthalates exposure may increase the risk of miscarriage in early pregnancy [22, 40–43]. As thyroid hormone is crucial to fetal neurodevelopment or essential for pregnant women during early pregnancy [12, 44–45], a control strategy for reducing phthalate exposure in pregnant women should be developed, as has been reported for children [46].

Some toxicological data provided supporting evidence on phthalate exposure, especially DnBP and DEHP, along with their effects on thyroid hormones, in pregnant animals or in vitro [10, 47–48]. Male Wistar rats exposed to high DEHP doses had significantly decreased serum T4 concentrations after 21 days [49], indicating thyroid hyperactivity. In vitro studies have revealed that DnBP might have possible T3-antagonist activity based on a thyroid hormone assay [50] and demonstrated that DnBP appeared to down-regulate human sodium/iodide symporter (NIS) [11] and MnBP could induce the expression of thyroid hormone receptor-beta [10, 47]. Recent study revealed that DEHP disrupts the growth/development of placenta, inhibits the proliferation of placenta and induces the apoptosis of placenta via activated MAPK in CD-1 mice [51]. As for mechanisms, some evidence has indicated that phthalate exposure might alter thyroid hormones by interacting with thyroid receptors and modulate the transcriptional activity of NIS. However, mechanism of how phthalates alter implement of zygote during early pregnancy is still unclear.

We evaluated some confounding factors such as TBG, urinary creatinine, gestational age, age, and other phthalate exposures. We found that thyroid-binding globins (TBG) were
significantly and positively (β: 1.45; p-value < 0.001) associated with serum T₄ in both models. Although TBG levels may vary or exceed the normal range during pregnancy, we did not find a significant correlation between TBG and gestational age in our participants (Table 3). Shen et al. showed MnBP could induce the expression of thyroid hormone receptor-beta [47], and Liu et al. revealed that DEHP could reduce thyroid hormones by interacting with thyroid-binding proteins [10]. It is possible that DnBP may alter human thyroxine by interacting with its receptors or TBG. Further, the serum creatinine of pregnant women may decrease by 10% and urine creatinine may vary in the first trimester because of physiological change in the glomerular filtration rate and renal blood flow [13, 52]. We used adjusted and unadjusted creatinine levels to evaluate the influence of creatinine in our model. We did not observe a significant change (<1%) in the prediction model that was consistent with a prior study [53]. A median to high correlation coefficient was observed for phthalate metabolite concentrations between adjusted and unadjusted creatinine levels that ranged from 0.84 to 0.92 (SI Table). The gestational age of our subjects might have narrowed in a certain period, which minimized the effects of unusually diluted or concentrated urinary creatinine levels. We did not find any significant effects regarding age, gestational age, or other phthalate exposure (MEP, MiBP, and MECPP) in our prediction model on T₄.

Our study explored the association between phthalate exposure and thyroid hormones in pregnant women 2 years after the 2011 Taiwan DEHP scandal. Although maternal thyroid hormone changes are linked to phthalate metabolite levels in urine, we still found a negative association between DnBP exposure and T₄ during early pregnancy. The fetal thyroid is essential during all aspects of fetus development and depends entirely on maternal thyroid hormones during early pregnancy [12, 44, 54]. It is important to diminish phthalate exposure for women prepare to pregnant and pregnant women during pregnancy, especially for personal care products, cosmetic and consumer products [20, 22, 55–57].

The present study had some strengths. We included TBG as a covariance to evaluate the potential influence of the natural physiology of thyroid hormones. Second, we measured 11 urinary phthalate metabolites in pregnant women to provide a solid internal-dose of phthalate exposure and to assess aggregate phthalate exposure from various sources [23]. Third, creatinine is influenced by muscle mass, racial differences, pregnancy, and dietary meat intake [57]. We conducted a sensitivity analysis for evaluating the effects of urinary creatinine on a multivariate regression model. The MBP level in a previous study [8] was the combination of MnBP and MiBP, so an assessment of the influence of individual DnBP and DiBP metabolites could not be performed. Therefore, we analyzed MnBP and MiBP to evaluate their individual effects on thyroid function, but this analysis might decrease the correlation as well.

There were some limitations in the present study. First, our study population was hospital based and relatively small. Second, we collected only 1 serum sample and 1-spot urine sample to measure the thyroid hormone and phthalate metabolite levels. Variations in our serum and urine samples might have underestimated the observed correlation [58]. Third, although phthalate metabolite levels might vary within a few days, it has been suggested that a single urine sample is a moderate indicator for phthalate metabolite measurement in pregnant women [9, 20]. Temporal variability in phthalate metabolites might have also reduced the correlation between thyroid hormone and urinary phthalate metabolite levels.

Conclusions
We found that the T₄ levels in pregnant women during early pregnancy were significantly and negatively associated with urinary MnBP levels after adjusting for age, gestation age, TBG, urinary creatinine, and exposures to other phthalate. TBG has been suggested to be a confounding
factor in evaluating thyroid hormones. Changes in T4 levels during early pregnancy might be a potential threat to fetal development or pregnant loss, and a strategy to reduce the exposure of pregnant women to phthalates should be emphasized.

Supporting Information

S1 Fig. Exposure profiles of 11 urinary phthalate metabolites in pregnant Taiwanese women (N = 97).

S1 Table. Pearson correlation coefficients between levels of creatinine unadjusted and creatinine adjusted phthalate metabolites.

S2 Table. Comparison of urinary phthalate metabolites (ng/mL) in pregnant women of Taiwan and other countries.

Acknowledgments

We thank to physicians, Dr. Chiung-Hsin Chang (M.D.) and Dr. Chen-Hsiang Yu (M.D.), and Ms. Cui-Bi Liao, the senior nurse, at the National Cheng Kung University Hospital, for their assistance of subject recruitment and specimen collection. We also deeply grateful to research assistants, Ms. Yu-Qiao Cheng, for the subject recruitment and data collection, and Mr. Chien-Jen Wang for his assistance in LC-MS/MS analysis. We also thanks for and funding support by the National Health Research Institutes (Grant No.: EH-102-PP-01, EH-103-PP-02, EH-104-PP-05, EM-105-PP-15).

Author Contributions

Conceived and designed the experiments: PCH PLK. Performed the experiments: WYL SSL. Analyzed the data: CHT WYL HBH. Contributed reagents/materials/analysis tools: PCH PLK. Wrote the paper: PCH. Specimen collections, sample arrangement and preparations: WYL SSL. Contributed to critical revision of the manuscript: PCH HBH PLK.

References

1. Huang PC, Tsai CH, Liang WY, Li SS, Pan WH, Chiang HC. Age and gender differences in urinary levels of eleven phthalate metabolites in general Taiwanese population after a DEHP episode. PLoS One. 2015; 10: e0133782. doi: 10.1371/journal.pone.0133782 PMID: 26207744
2. Huang PC, Liou SH, Ho IK, Chiang HC, Huang HI, Wang SL. Phthalates exposure and endocrinal effects: an epidemiological review. J Food Drug Anal. 2012; 20: 719–733.
3. Wu MT, Wu CF, Wu JR, Chen BH, Chen EK, Chao MC, et al. The public health threat of phthalate-tainted foodstuffs in Taiwan: the policies the government implemented and the lessons we learned. Environ Int. 2012; 44: 75–79. doi: 10.1016/j.envint.2012.01.014 PMID: 22361240
4. Kuo FC, Su SW, Wu CF, Huang MC, Shiea J, Chen BH, et al. Relationship of urinary phthalate metabolites with serum thyroid hormones in pregnant women and their newborns: a prospective birth cohort in Taiwan. PLoS One. 2015; 10: e0123884. doi: 10.1371/journal.pone.0123884 PMID: 26042594
5. Tsai HJ, Chen BH, Wu CF, Wang SL, Huang PC, Tsai YC, et al. Intake of phthalate-tainted foods and microalbuminuria in children: The 2011 Taiwan food scandal. Environ Int. 2016; 89-90: 129–137. doi: 10.1016/j.envint.2016.01.015 PMID: 26827184
6. Tsai YA, Lin CL, Hou JW, Huang FC, Lee MC, Chen BH, et al. Effects of high di(2-ethylhexyl) phthalate (DEHP) exposure due to tainted food intake on pre-pubertal growth characteristics in a Taiwanese population. Environ Res. 2016; 149: 197–205. doi: 10.1016/j.envres.2016.05.005 PMID: 27209343
7. Meeker JD, Ferguson KK. Relationship between urinary phthalate and bisphenol A concentrations and serum thyroid measures in U.S. adults and adolescents from the National Health and Nutrition Examination Survey (NHANES) 2007–2008. Environ Health Perspect. 2011; 119: 1396–1402. doi: 10.1289/ehp.1103582 PMID: 21749963

8. Huang PC, Kuo PL, Chou YY, Lin SJ, Lee CC. Associations between urinary phthalate monoesters and thyroid hormones in pregnant women. Hum Reprod. 2007; 22: 2715–2722. PMID: 17704099

9. Johns LE, Ferguson KK, Soldin OP, Cantonwine DE, Rivera-González LO, Del Toro LV, et al. Urinary phthalate metabolites in relation to maternal serum thyroid and sex hormone levels during pregnancy: a longitudinal analysis. Reprod Biol Endocrinol. 2015; 13: 4. doi: 10.1186/1477-7827-13-4 PMID: 25596636

10. Liu C, Zhao L, Wei L, Li L. DEHP reduces thyroid hormones via interacting with hormone synthesis-related proteins, deiodinases, transthyretin, receptors, and hepatic enzymes in rats. Environ Sci Pollut Res Int. 2015; 22: 12711–12719. doi: 10.1007/s11356-015-4567-7 PMID: 25913319

11. Breous E, Wenzel A, Loos U. The promoter of the human sodium/iodide symporter responds to certain phthalate plasticisers. Mol Cell Endocrinol. 2005; 244: 75–78. PMID: 16257484

12. Ohara N, Tsujino T, Maruo T. The role of thyroid hormone in trophoblast function, early pregnancy maintenance, and fetal neurodevelopment. J Obstet Gynaecol Can. 2004; 26: 982–990. PMID: 15560861

13. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD. Williams Obstetrics, 22nd edn. New York, NY: McGraw-Hill, 2006.

14. Morreale de Escobar G, Obregón MJ, Escobar del Rey F. Maternal thyroid hormones early in pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab 2004; 18: 225–248.

15. de Cock M, de Boer MR, Lamoree M, Legler J, van de Bor M. Prenatal exposure to endocrine disrupting chemicals in relation to thyroid hormone levels in infants—a Dutch prospective cohort study. Environ Health. 2014; 13: 106. doi: 10.1186/1476-069X-13-106 PMID: 25495114

16. Huang PC, Kuo PL, Chou YY, Lin SJ, Lee CC. Association between prenatal exposure to phthalates and the health of newborns. Environ Int 2009; 35: 14–20. doi: 10.1016/j.envint.2008.05.012 PMID: 18640725

17. Huang PC, Liou LH, Shie RH, Tsai CH, Liang WY, Wang CW, et al. Assessment of urinary thioglycolic acid exposure in school-aged children in the vicinity of a Petrochemical complex in central Taiwan. Environ Res. 2015 Dec 4 (Article in Press, doi: 10.1016/j.envres.2015.11.027).

18. Swan SH, Sathyanarayana S, Barrett ES, Janssen S, Liu F, Nguyen RH, et al. First trimester phthalate exposure and anogenital distance in newborns. Hum Reprod. 2015; 30: 963–972. doi: 10.1093/humrep/deu363 PMID: 25697839

19. Arbuckle TE, Davis K, Marro L, Fisher M, Legrand M, LeBlanc A, et al. Phthalate and bisphenol a exposure among pregnant women in Canada-results from the MIREC study. Environ Int. 2014; 68: 55–65. doi: 10.1016/j.envint.2014.02.010 PMID: 24709781

20. Cantonwine DE, Cordero JF, Rivera-González LO, Anzalota Del Toro LV, Ferguson KK, Mukherjee B, et al. Urinary phthalate metabolite concentrations among pregnant women in Northern Puerto Rico: distribution, temporal variability, and predictors. Environ Int. 2014; 62: 1–11. doi: 10.1016/j.envint.2013.09.014 PMID: 24161445

21. Zota AR, Calafat AM, Woodruff TJ. Temporal trends in phthalate exposures: findings from the National Health and Nutrition Examination Survey, 2001–2010. Environ Health Perspect. 2014; 122: 235–241. doi: 10.1289/ehp.1306681 PMID: 24425099

22. Mu D, Gao F, Fan Z, Shen H, Peng H, Hu J. Correction to levels of phthalate metabolites in urine of pregnant women and risk of clinical pregnancy loss. Environ Sci Technol. 2015; 49: 13081. doi: 10.1021/acs.est.5b04255 PMID: 26473648

23. Braun JM, Just AC, Williams PL, Smith KW, Calafat AM, Hauser R. Personal care product use and urinary phthalate metabolite and paraben concentrations during pregnancy among women from a fertility clinic. J Expo Sci Environ Epidemiol. 2014; 24: 459–466. doi: 10.1038/jes.2013.69 PMID: 24149971

24. Just AC, Adibi JI, Rundle AG, Calafat AM, Camann DE, Hauser R, et al. Urinary and air phthalate concentrations and self-reported use of personal care products among minority pregnant women in New York city. J Expo Sci Environ Epidemiol. 2010; 20: 625–633. doi: 10.1038/jes.2010.13 PMID: 20354564

25. Ferguson KK, Colacino JA, Lewis RC, Meeker JD. Personal care product use among adults in NHANES: associations between urinary phthalate metabolites and phenols and use of mouthwash and sunscreen. J Expo Sci Environ Epidemiol. 2016 May 11. doi: 10.1038/jes.2016.27

26. Serrano SE, Kerr CJ, Seixas NS, Nguyen RH, Barrett ES, Janssen S, et al. Dietary phthalate exposure in pregnant women and the impact of consumer practices. Int J Environ Res Public Health. 2014; 11: 6193–6215. doi: 10.3390/ijerph110606193 PMID: 24927036
27. Guo Y, Zhang Z, Liu L, Li Y, Ren N, Kannan K. Occurrence and profiles of phthalates in foodstuffs from China and their implications for human exposure. J Agric Food Chem. 2012; 60: 6913–6919. doi:10.1021/jf3021128 PMID: 22703192

28. Silva MJ, Reidy JA, Herbert AR, Preau JL Jr, Needham LL, Calafat AM. Detection of phthalate metabolites in human amniotic fluid. Bull Environ Contam Toxicol 2004; 72: 1226–1231. PMID: 15362453

29. Jensen MS, Anand-Ivell R, Nørgaard-Pedersen B, Jönsson BA, Bonde JP, Hougaard DM, et al. Amniotic fluid phthalate levels and male fetal gonad function. Epidemiology. 2015; 26: 91–99. doi:10.1097/EDE.0000000000000198 PMID: 25384265

30. Calafat AM, Brock JW, Silva MJ, Gray LE Jr, Reidy JA, Barr DB, et al. Urinary and amniotic fluid levels of phthalate monoesters in rats after the oral administration of di(2-ethylhexyl) phthalate and di-n-butyl phthalate. Toxicology. 2006; 217: 22–30. PMID:16171919

31. Wittassek M, Angerer J, Kolossa-Gehring M, Schäfer SD, Klockenbusch W, Dobler L, et al. Fetal exposure to phthalates—a pilot study. Int J Hyg Environ Health. 2009; 212: 492–498. doi:10.1016/j.ijheh.2009.04.001 PMID: 19423389

32. Carter AM. Animal models of human placentation—a review. Placenta. 2007; 28 Suppl A: S41–7. PMID: 17196252

33. Li LX, Chen L, Meng XZ, Chen BH, Chen SQ, Zhao Y, et al. Exposure levels of environmental endocrine disruptors in mother-newborn pairs in China and their placental transfer characteristics. PLoS One. 2013; 8: e62526. doi:10.1371/journal.pone.0062526 PMID: 23667484

34. Chaouat G, Clark DA. Are animal models useful or confusing in understanding the human feto-maternal relationship? A debate. J Reprod Immunol. 2015; 108: 56–64. doi:10.1016/j.jri.2014.10.004 PMID: 25534633

35. Schmidt A, Morales-Prieto DM, Pastushek J, Fröhlich K, Markert UR. Only humans have human placentas: molecular differences between mice and humans. J Reprod Immunol. 2015; 108: 65–71. doi:10.1016/j.jri.2015.03.001 PMID: 25817465

36. Mose T, Mortensen GK, Hedegaard M, Knudsen LE. Phthalate monoesters in perfusate from a dual placenta perfusion system, the placenta tissue and umbilical cord blood. Reprod Toxicol. 2007; 23: 83–91. PMID:17049806

37. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN, Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharm. 1999; 36: 439–452.

38. Boas M, Frederiksen H, Feldt-Rasmussen U, Skakkebæk NE, Hegedüs L, Hilsted L, et al. Childhood exposure to phthalates: associations with thyroid function, insulin-like growth factor I, and growth. Environ Health Perspect. 2010; 118: 1458–1464. doi:10.1289/ehp.0901331 PMID: 20621847

39. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab. 2010; 95: E44–48. doi:10.1210/jc.2010-0340 PMID: 20534758

40. Bernardi LA, Cohen RN, Stephenson MD. Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss. Fertil Steril. 2013; 100: 1326–1331. doi:10.1016/j.fertnstert.2013.07.1975 PMID: 23954357

41. Hammond KR, Cataldo NA, Hubbard JA, Malizia BA, Steinkampf MP. Gestational hypothyroidism: development of mild hypothyroidism in early pregnancy in previously euthyroid women. Fertil Steril. 2015; 103: 1532–1536.e1. doi:10.1016/j.fertnstert.2015.03.006 PMID: 25910570

42. Maraka S O’Keeffe DT, Montori VM. Subclinical hypothyroidism during pregnancy—should you expect this when you are expecting?: A teachable moment. JAMA Intern Med. 2015; 175: 1088–1089. doi:10.1001/jamainternmed.2015.1348 PMID: 25938470

43. Morreale de Escobar G. The role of thyroid hormone in fetal neurodevelopment. J Pediatr Endocrinol Metab. 2001; 14 Suppl 6: 1453–1462. PMID: 11837499

44. Huang HB, Chen HY, Su PH, Huang PC, Sun CW, Wang CJ, et al. Fetal and childhood exposure to phthalate diesters and cognitive function in children up to 12 years of age: Taiwanese maternal and infant cohort study. PLoS One. 2015; 10: e0131910. doi:10.1371/journal.pone.0131910 PMID: 26121592

45. Chen CY, Chou YY, Lin SJ, Lee CC. Developing an intervention strategy to reduce phthalate exposure in Taiwanese girls. Sci Total Environ. 2015; 517: 125–131. doi:10.1016/j.scitotenv.2015.02.021 PMID: 25725197
47. Shen O, Wu W, Du G, Liu R, Yu L, Sun H, et al. Thyroid disruption by Di-n-butyl phthalate (DBP) and mono-n-butyl phthalate (MBP) in Xenopus laevis. PLoS One. 2011; 6: e19159. doi:10.1371/journal.pone.0019159 PMID: 21544203

48. Li N, Wang D, Zhou Y, Ma M, Li J, Wang Z. Dibutyl phthalate contributes to the thyroid receptor antagonistic activity in drinking water processes. Environ Sci Technol. 2010; 44: 6863–6868. doi:10.1021/es101254c PMID: 20681736

49. Hinton RH, Mitchell FE, Mann A, Chescoe D, Price SC, Nunn A, et al. Effects of phthalic-acid esters on liver and thyroid. Environ Health Perspect. 1986; 70: 195–210. PMID:3830106

50. Sugiyama S, Shimada N, Miyoshi H, Yamauchi K. Detection of thyroid system-disrupting chemicals using in vitro and in vivo screening assays in Xenopus laevis. Toxicol Sci. 2005; 88: 367–374. PMID: 16179385

51. Zong T, Lai L, Hu J, Guo M, Li M, Zhang L, et al. Maternal exposure to di-(2-ethylhexyl) phthalate disrupts placental growth and development in pregnant mice. J Hazard Mater. 2015; 297: 25–33. doi:10.1016/j.jhazmat.2015.04.065 PMID: 25935407

52. James DK, Steer PJ, Weiner CP, Gonik B. High Risk Pregnancy: Management Options, 3rd edn. Philadelphia, PA: Elsevier-Saunders, 2005.

53. Braun JM, Smith KW, Williams PL, Calafat AM, Berry K, Ehrlich S, et al. Variability of urinary phthalate metabolite and bisphenol A concentrations before and during pregnancy. Environ Health Perspect. 2012; 120: 739–745. doi:10.1289/ehp.1104139 PMID: 22262702

54. Zoeller RT, Rove J. Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. Neuroendocrinology 2004; 16: 809–818.

55. Buckley JP, Palmieri RT, Matuszewski JM, Herring AH, Baird DD, Hartmann KE, et al. Consumer product exposures associated with urinary phthalate levels in pregnant women. J Expo Sci Environ Epidemiol. 2012; 22: 468–475. doi:10.1038/jes.2012.33 PMID: 22760436

56. Schettler T. Human exposure to phthalates via consumer products. Int J Androl. 2006; 29: 134–139; discussion 181–185. PMID: 16466533

57. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005; 113: 192–200. PMID: 15687057

58. Hashimoto K, Yamakita N, Ikeda T, Matsuhisa T, Kuwayama A, Sano T, et al. Longitudinal study of patients with idiopathic isolated TSH deficiency: possible progression of pituitary dysfunction in lymphocytic adenohypophysitis. Endocr J. 2006; 53: 593–601. PMID: 16896268